Phase 2a trials are planned in both RA and hidradenitis suppurativa ... to treating inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental component of the ...

Phase 2a trials are planned in both RA and hidradenitis suppurativa ... to treating inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental component of the ...

Oss, Netherlands – 09 December 2024 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps ...

The funding will enable next steps for the clinical development of CIT-013, a first-in-class monoclonal antibody which targets Neutrophil Extracellular Traps ... both RA and hidradenitis ...

Phase 2a trials are planned in both RA and hidradenitis suppurativa (HS), intended to establish CIT-013's ... Citryll is pioneering a transformative approach to treating inflammatory diseases by ...

designed to target neutrophil extracellular traps (NETs), which play a key role in inflammation and have not been previously therapeutically targeted. Novartis Venture Fund, Johnson & Johnson ...